TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05389423
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2/day administered by CIVI on days 1 to 4
Study: NCT05389423
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 administered IV on day 5
Study: NCT05619744
Drug: RO7616789
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
Study: NCT05275868
Drug: MGY825
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT05775536
Drug: Aspirin 500Mg Tab
Normalized name: ASPIRIN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
Study: NCT05874921
Drug: Jelmyto (mitomycin) for pyelocalyceal solution
Normalized name: Jelmyto Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
Study: NCT06550180
Drug: Spinal anaesthesia group (S)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
Study: NCT06061848
Drug: ILIT + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
Study: NCT05102409
Drug: Xiidra® (5% lifitegrast ophthalmic solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiidra® (5% lifitegrast ophthalmic solution) dosed once
Study: NCT06430307
Drug: Saussurea Involucrata Liquid Tonic
Normalized name: Saussurea involucrata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
Study: NCT05801107
Drug: WX-0593
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
Study: NCT04903821
Drug: BAY3427080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
Study: NCT05346445
Drug: Fluoxetine 20 MG
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received non-hormonal treatment with fluoxetine.
Study: NCT06701110
Drug: [U-14C] WX-081
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
Study: NCT06537908
Drug: Anti-PD-1/PD-L1 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
Study: NCT06137365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
Study: NCT05505994
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 A mg tablet
Study: NCT05279898
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion
Study: NCT05505994
Drug: DWP16001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 Placebo tablet
Study: NCT06703840
Drug: LIB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIB-01 oral suspension
Study: NCT06703840
Drug: LIB-01 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIB-01 Placebo oral suspension
Study: NCT05687916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-861 placebo matching tablets.
Study: NCT05909800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administred orally, once daily, for 12 months.
Study: NCT06004401
Drug: Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin
Normalized name: bismuth / pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
Study: NCT06004401
Drug: Vonopazan +Minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonopazan 20mg 2/day+Minocycline 100mg 2/day
Study: NCT06004401
Drug: Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin
Normalized name: bismuth / pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
Study: NCT05805956
Drug: IMM2902
Approvals — FDA: no, EMA: no, PMDA: no
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Study: NCT06401798
Drug: NCWP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose gel combined with NCWP was applied topically to the pocket
Study: NCT04957914
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00864409
Drug: saline.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 170 mL sterile saline
Study: NCT05356728
Drug: Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
Study: NCT06516302
Drug: GR1802
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR1802 will be administered SC.
Study: NCT06516302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered SC.
Study: NCT05805683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
Study: NCT05038410
Drug: Wobenzym®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobenzym®
Study: NCT04898894
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecal (IT)
Study: NCT04898894
Drug: methotrexate/hydrocortisone/cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intrathecal (IT)
Study: NCT06003179
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning chemo at different doses
Study: NCT05683496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05244642
Drug: Investigator's choice of Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
Study: NCT05851976
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg twice daily for 16 days
Study: NCT05173142
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-453 administered orally.
Study: NCT04822584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day orally for 36 weeks
Study: NCT04461041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
Study: NCT06397781
Drug: Skin Cleanser Combination No.1
Normalized name: skin cleanser combination no.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily.
Study: NCT06088732
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single oral dose of Ibuprofen
Study: NCT06088732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT06119945
Drug: DWJ1568
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of DWJ1568
Study: NCT06119945
Drug: DWC202215
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of DWC202215
Study: NCT05051930
Drug: TQC3721 suspension for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
Study: NCT05051930
Drug: TQC3721 suspension placebo for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
Study: NCT06652048
Drug: Furmonertinib 160mg QD plus Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
Study: NCT06038916
Drug: STSA-1002 Injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06038916
Drug: STSA-1002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04839575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (daily)
Study: NCT06156761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study: NCT06156761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
Study: NCT04647487
Drug: LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05911282
Drug: N Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study.
Study: NCT06002789
Drug: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
Study: NCT06002789
Drug: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
Study: NCT04998201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Normal Saline (0.9% NaCl)
Study: NCT06406829
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
Study: NCT06209385
Drug: YZJ-5053 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: YZJ-5053 tablets will be administrated orally QD for 21 days
Study: NCT06430827
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
Study: NCT06610279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 matching placebo SC injection
Study: NCT05273749
Drug: TNX-102 SL Tablet, 5.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT05273749
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT06325930
Drug: [14C]-HU6
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
Study: NCT06154447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for Oral Administration
Study: NCT06154447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension and Tablets for Oral Administration
Study: NCT04647890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules once daily for 12 weeks
Study: NCT05048069
Drug: Mucosta®SR Tablets 150mg(Rebamipide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
Study: NCT05567094
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Study: NCT06392321
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison between bupivacaine, bupivacaine and fentanyl.
Study: NCT06702943
Drug: Tigecycline (Tygacil)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
Study: NCT06519266
Drug: IPI1/NIVO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Study: NCT06519266
Drug: IPI3/NIVO1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Study: NCT05146219
Drug: TY-9591 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY-9591 Tablets 160mg/d
Study: NCT02179138
Drug: TFV 1% gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05876858
Drug: 11C-butanol
Normalized name: BUTANOLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Study: NCT04906473
Drug: KY100001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY100001; Tablet; Oral route; Dose escalation and dose extension
Study: NCT05641896
Drug: [18F]FAPI-74 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
Study: NCT05262556
Drug: NP-101 (TQ Formula)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
Study: NCT05080790
Drug: Dinutuximab Beta, Zoledronic acid, Interleukin-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
Study: NCT04827875
Drug: AIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal
Study: NCT06625177
Drug: TEV-53408
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV-53408 injection administered subcutaneously
Study: NCT05768139
Drug: STX-478
Normalized name: STX-478
Approvals — FDA: no, EMA: no, PMDA: no
Description: STX-478 is a mutant-selective PI3Kα inhibitor
Study: NCT05236387
Drug: 99m Tc-TM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
Study: NCT06637631
Drug: SAR441566 matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05761015
Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.
Study: NCT04804514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is applied to teeth
Study: NCT06636734
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05384197
Drug: Enhanced regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)
Study: NCT05384197
Drug: Extended regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)
Study: NCT06045429
Drug: Oroxid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash.
Study: NCT05027373
Drug: SSGJ-613
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
Study: NCT05027373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
Study: NCT05906511
Drug: 2mg Purified THC in an ethanolic solution
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg Purified THC in an ethanolic solution
Study: NCT05906511
Drug: 4mg Purified THC in an ethanolic solution
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg Purified THC in an ethanolic solution